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or caspofungin acetate (CAS). Endpoints were sur- 
vival, colony forming units (CFUs), and histology of 
lungs. 
Results: Initially, we compared the efficacy of a 
single dose of LAmB at 15 mg/kg to a dual treat- 
ment close of 7.5mg/kg given every other day. 
The single 15mg/kg close and the second of the 
dual 7.5 mg/kg doses were administered 24, 48 or 
72 hours prior to infection. Only administration of 
dual 7.5 mg/kg doses of LAmB at 24 or 48 h prior to 
infection resulted in equivalent, significant protec- 
tion as compared to placebo (100% vs 50%, p <0.05). 
This data indicated that the total amount of LAmB 
administered over time was more important han 
the individual amount of each dose. Next, we com- 
pared dual doses of LAmB at 7.5 mg/kg with ABLC 
at 7.5 mg/kg, AmB at 1 mg/kg, and CAS at 1 mg/kg 
given on days -4 and -2 prior to infection. Addi- 
tionally, CAS was also administered as a single dose 
6 hours prior to infection. Only LAmB and the single 
dose arm of CAS significantly improved survival 
compared to placebo (75% and 88% vs 25% survival 
of placebo, p < 0.04). Lung CFUs was significantly 
reduced by prophylactic administration of LAmB 
(p=0.005), AmB (p=0.03), or CAS (given 6 h prior 
to infection, p=0.0002) but not ABLC. These re- 
suits were mirrored in histopatho[ogica[ evaluation 
since lungs from mice receiving placebo and ABLC 
revealed large amounts of elongated hyphae with 
moderate necrotizing pneumonia, whereas lungs of 
mice treated with LAMB, AmB, or CAS did not. 
Conclusions: These data indicate that LAmB ad- 
ministered aily or every other day is a promising 
candidate for prophylaxis against pulmonary as- 
pergillosis in neutropenic hosts. CAS also mediates 
prophylactic effect, but must be dosed more often 
than LAmB for efficacy. 
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Background: Severe adenovirus infections are of 
increasing concern in AIDS patients and trans- 
plant recipients under immunosuppressive th rapy. 
Unfortunately, current therapeutic moda[ities for 
adenovirus infections are limited. 
Objectives: We investigated the contribution of 
the host's adaptive immune response and the ef- 
ficacy of immunotherapy in the control of systemic 
adenovirus infections using two mouse models. 
Methods ~ Results: Severe combined immune 
deficient (SClD) mice, intranasa[[y inoculated with 
mouse adenovirus type 1 (MAV-1), develop a fa- 
tal disseminated isease characterized by hem- 
orrhagic enteritis (Lenaerts et aL, 2005, Antimi- 
crob Agents Chemother 49, 4689-99). When SCID 
mice were treated with antisera containing MAV-1 
specific IgG, MAV-l-induced death was significantly 
delayed from day 18 p.i. (untreated mice) to day 
42-60 p.i. (antiserum-treated mice). The extent of 
the delay was dependent on the titer of MAV-1 neu- 
tralizing antibodies in the antiserum. The MAV-1 
antisera were obtained from immunocompetent 
mice challenged with MAV-1 and were transferred 
to the MAV-l-infected SCID mice at day -1 and 
day 9 post infection. Ultimately, MAV-l-infected 
SCID mice treated with the MAV-l-antisera showed 
100% mortality, with identical pathology and simi- 
lar virus titers in the target organs as seen in un- 
treated, infected SCID mice. These results indicate 
that antibodies play a major role in protection and 
elimination of systemic adenovirus infection. In an 
alternative mouse mode[ for adenovirus infection, 
cyc[ophosphamide (CY) was administered to adult 
BALB/c mice to induce a genera[ and reversible 
immunosuppression. MAV-l-re[ated mortality cor- 
related with the duration of immunosuppressive 
therapy. Mice receiving CY for 3 or more weeks 
succumbed to an identical pathology and similar 
virus titers in the affected tissues as seen with 
MAV-l-infected SCID mice. On the contrary, mice 
in which immunosuppressive therapy was ceased 
1 week post infection did not develop symptoms 
and survived. These mice showed high serum titers 
(~>1:160) of MAV-1 neutralizing antibodies. Studies 
are ongoing to evaluate the efficacy of antivira[s 
(such as cidofovir) in this MAV-1/CY mode[. 
Conclusions: These two new mouse models wi[[ in- 
crease our understanding of the suppression of ade- 
novirus disease by antivira[ and/or immunotherapy 
and wi[[ be helpful in the development of an ade- 
quate treatment for systemic adenovirus infections 
in immunocompromised patients. 
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Background: Advisability of vaccination against the 
HBV infection in patients with 'isolated' HBcAb 
